Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback